MedTrace Logo

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

NCT00422461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2021-10-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure

Conditions

Interventions

DRUG

placebo

placebo, oral, tablets, once daily, for 28 days

DRUG

PF-00489791

PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days

DRUG

PF-00489791

PF-00489791 4 mg, oral, tablets, once daily, for 28 days

DRUG

PF-00489791

PF-00489791 10 mg, oral, tablets, once daily, for 28 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-27
Primary Completion
2008-01-28
Completion
2008-01-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422461 on ClinicalTrials.gov